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Abstract: Therapy of melanoma using T-cells with genetically introduced T-cell receptors 
(TCRs) directed against a tumor-selective cancer testis antigen (CTA) NY-ESO1 demonstrated 
clear antitumor responses in patients without side effects. Here, we exploited the concept of 
TCR-mediated targeting through introduction of single-chain variable fragment (scFv) antibodies 
that mimic TCRs in binding major histocompatibility complex-restricted CTA. We produced 
scFv antibodies directed against Melanoma AntiGEn A1 (MAGE A1) presented by human 
leukocyte antigen A1 (HLA-A1), in short M1/A1, and coupled these TCR-like antibodies to 
liposomes to achieve specific melanoma targeting. Two anti-M1/A1 antibodies with different 
ligand-binding affinities were derived from a phage-display library and reformatted into scFvs 
with an added cysteine at their carboxyl termini. Protein production conditions, ie, bacterial strain, 
temperature, time, and compartments, were optimized, and following production, scFv proteins 
were purified by immobilized metal ion affinity chromatography. Batches of pure scFvs were 
validated for specific binding to M1/A1-positive B-cells by flow cytometry. Coupling of scFvs 
to liposomes was conducted by employing different conditions, and an optimized procedure was 
achieved. In vitro experiments with immunoliposomes demonstrated binding of M1/A1-positive 
B-cells as well as M1/A1-positive melanoma cells and internalization by these cells using flow 
cytometry and confocal microscopy. Notably, the scFv with nonenhanced affinity of M1/A1, 
but not the one with enhanced affinity, was exclusively bound to and internalized by melanoma 
tumor cells expressing M1/A1. Taken together, antigen-mediated targeting of tumor cells as 
well as promoting internalization of nanoparticles by these tumor cells is mediated by TCR-like 
scFv and can contribute to melanoma-specific targeting.
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Introduction
Melanoma patients with metastasized disease are in great need for new treatment 
modalities as survival rates are generally low. Recently, important progress has 
been made with the combination of so-called checkpoint inhibitors.1–4 The improved 
progression-free survival in previously untreated melanoma patients, when an antibody 
that blocks CTLA-4 combined with an antibody blocking PD-1 are administered, 
indicates the potential of immunotherapy in melanoma.1 Likewise, adoptive T-cell 
therapy, in which T-cells are administered after expansion outside the patient, shows 
promise. An improvement of that approach was achieved with the introduction of 
a genetically engineered T-cell receptor (TCR) in T-cells followed by expansion 
and administration. This method of TCR introduction results in T-cells which can 
be forced to target specific antigens expressed only by cancer cells.5–8 To mimic the 
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TCR function, antibodies and single-chain variable frag-
ments (scFv) were produced showing specific binding and 
cell kill. Previously, Willemsen et al5 demonstrated T-cell 
targeting to melanoma cells using the G8 Fab fragment. The 
use of antibodies has several advantages compared to TCRs. 
Antibodies are easier to produce, when introduced on T-cells 
do not recombine with wild-type TCRs, have a higher affin-
ity, and can be used to target nanomaterials.9 Here, we used 
TCR-mimicking scFvs to target lipid-based nanoparticles, ie, 
liposomes, specifically to a melanoma peptide in the context 
of the major histocompatibility complex (MHC).
Among common nanosystems as classified by Torchilin,10 
liposomes fall under the classification of nanoparticu-
late pharmaceutical drug delivery systems. Rigon et al11 
discussed in their recent review the application of these 
nanotechnology-based drug delivery systems as therapy 
for melanoma. There have been many reported advantages 
including high drug stability, bioavailability, better tissue/
organ distribution, blood retention, minimized toxic effects, 
and better blood circulation time. Targeted nanoparticle drug 
delivery as a concept and methods of enhancing the effect in 
melanoma has been discussed elsewhere.12 Development of 
multifunctional particles provide an opportunity to increased 
blood circulation time, better accumulation in tumors, and 
high efficacy, as shown in previous studies. Liposomes are 
used as carriers for chemotherapy, immunocytokines, and for 
instance, siRNA to enhance melanoma treatment efficacy.13 
Chen et al13 further outline the use of nanoparticles in detec-
tion, diagnosis, and treatment of melanoma. In our study, we 
focus on liposomes for active targeting to melanoma.
Liposomes are lipid-based hollow nanoparticles which 
can be used to contain and deliver hydrophobic and hydro-
philic compounds. Encapsulation of therapeutic compounds 
in liposomes dramatically changes their pharmacokinetics: it 
extends blood residence time and prevents degradation and 
clearance. For clinical use, and especially in the cancer field, 
these liposomes are around 100 nm in size and are coated 
with polyethylene glycol (PEG), which prevents opsoniza-
tion and recognition by macrophages and further increases 
circulation time.14–16 Because of liposome size and their 
capacity to remain in the blood, passive accumulation in 
tumors is observed, which is believed to result from leaky and 
permeable vessels in tumors, and is also designated enhanced 
permeability and retention effect.17 Modified PEGylated lipo-
somes can be further used to target antigens by decorating 
the liposome surface with antibodies,18–20 which results in 
increased accumulation in tumor cells as compared to healthy 
tissue.21 Targeting moieties on liposomes can facilitate 
prolonged retention of the nanocarrier in the tumor, but may 
also improve uptake by tumor cells.18,21 Through careful 
selection of the target and liposome composition, liposomal 
processing can be manipulated and tuned to need.
The aim of this study was the formulation of immunolipo-
somes targeting melanoma-specific peptides when expressed 
by MHC molecules on the surface of tumor cells. All nucle-
ated cells express MHC molecules and present processed 
protein fragments to be recognized by T-cells through their 
TCR. This peptide–MHC has been used to generate TCR-
like scFvs, which are coupled to the outside of liposomes. 
We focused on MHC class I to attract CD8+ T-cells, which 
can inflict direct damage to the cells they attack. Among the 
group of MHC class I presented peptides, we have selected 
peptides derived from cancer testis antigens (CTAs) due to 
the selective expression of certain CTAs by tumors and not 
healthy cells, except for MHC-negative germ line cells.22–24 
CTAs are described to be restricted to human germ line cells, 
but are also present in certain malignant tumors.22 Melanoma 
AntiGEn A1, (MAGE A1), was the first CTA against which 
a cytotoxic T-lymphocyte reaction was discovered by van 
der Bruggen et al.25 MAGEs are however not restricted to 
melanoma but are expressed at the protein level by a range of 
tumors, such as esophageal carcinoma, lung adenocarcinoma, 
and head and neck carcinoma,22,26,27 making them an ideal 
target for nanocarrier-based therapy.
In an effort to obtain TCR-like binding molecules, we 
have selected M1/A1-specific Fab molecules via phage-
display library (M1/A1 stands for MAGE A1 presented by 
HLA-A1 [human leukocyte antigen A1]).28,29 Fab fragments 
used for this study differ a log-scale in their affinity for M1/A1 
(Fab G8 K
D
 =250 nM and Fab Hyb3 K
D
 =14 nM).29 The dif-
ference in ligand-binding affinity will allow us to compare 
the importance of this parameter for multivalent nanopar-
ticles. These Fab fragments were reformatted into scFvs5,29 to 
facilitate coupling to liposomes. scFv are the smallest format 
of antibodies that retain a complete antigen binding site, but 
lack an Fc domain and a complement-activating region.19 
Notably, scFv retain binding of antigen with high affinity, but 
with a potentially reduced immunogenicity.19 It is crucial to 
use relatively small targeting moieties, since previous studies 
demonstrated that using whole monoclonal antibodies on nano-
carriers to target tumors resulted in rapid clearance from the 
bloodstream impairing the usefulness of these devices.19,30
Here, we describe the formulation of immunoliposomes 
that target uniquely expressed M1/A1 antigen on mela-
noma cells. Escherichia coli bacteria were used to prepare 
anti-M1/A1 scFvs. These fragments were assessed for their 
binding of M1/A1-positive cells by flow cytometry. When 
binding criteria were met, scFvs were coupled to liposomes 
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and subjected to various characterization steps before use 
on cells. Characterization included quantitative and quali-
tative tests to determine the total lipid and protein levels, 
liposome characteristics, and assessment of binding to M1/
A1-positive cells. Once validated, immunoliposome batches 
were released for further in vitro testing of their targeting 
ability toward melanoma cells. We demonstrate that immu-
noliposomes coupled to anti-M1/A1 scFvs represent a novel 
formulation based on TCR mimicry that allows successful 
targeting to tumor cells.
Materials and methods
Restriction enzymes (NotI and SfiI), NEB buffer, BSA, 
and Nucleobond Xtra Midi were purchased from Bioke 
(Leiden, the Netherlands); pABC4 vector was a kind gift by 
Prof Kontermann (Stuttgart, Germany); DH5α E. coli was 
purchased from Invitrogen (Leek, the Netherlands); BL21 
bacteria was from Cell Biology Department and HB2151 
was from Tumor Immunology lab (Eramus MC, Rotterdam, 
the Netherlands); TG1 electrocompetent cells were purchased 
from Bio-connect (Huissen, the Netherlands); DNA Clean 
and Concentrator Kit and Zymoclean Gel DNA Recovery 
Kit was purchased from Baseclear (Leiden, the Netherlands); 
tryptone, yeast, NaCl, glucose, sucrose, β-mercaptanol, imida-
zole, EDTA, l-cysteine, HEPES, choloroform, and methanol 
from Sigma (Zwijndrecht, the Netherlands); tris glycine and 
bis-Tris precasted gels, tris-glycine buffer, and MOPS buffer 
from Novex (Amsterdam, the Netherlands); immobilized 
metal affinity chromatography (IMAC) Ni2+ columns and 
AKTA FPLC system from GE Healthcare (Hoevelaken, the 
Netherlands); phosphate-buffered saline (PBS) and Amicon 
filters MWCO 10,000 from Millipore (Amsterdam, the 
Netherlands); dialysis cassettes from Pierce scientific; and 
tris carboxyethyl phosphine (TCEP) beads and powder and 
Pierce spin cups cellulose acetate filters from Thermo Sci-
entific (Bleiswijk, the Netherlands). Other chemicals used 
were of HPLC grade. Horseradish peroxidase (HRP) conju-
gated anti-HIS-tag antibody was purchased from Santa Cruz 
(Dallas, TX, USA), mouse anti-HIS-tag antibody was from 
Santa Cruz, Sanbio (Mountain View, CA, USA) and Abcam 
(Cambridge, MA, USA), goat anti-mouse PE from Southern 
Biotech (human ads-PE) (Uithoorn, the Netherlands), 7-AAD 
from Beckton and Dickinson (Breda, the Netherlands), and 
mouse anti-M13 antibody and HRP-tagged anti-M13 anti-
body from GE Healthcare (Leiderdorp, the Netherlands). 
The lipids, hydrogenated soy l-α-phosphatidylcholine 
(HSPC), cholesterol, 1,2-distearoyl-sn-glycero-3-phospho-
ethanolamine-N-PEG
2000
 (DSPE-PEG
2000
) were purchased 
from Lipoid (Ludwigshafen, Germany), and 1,2-distearoyl-sn- 
glycero-3-phospho ethanolamine-N-26 (ammonium salt) 
(DSPE-PEG
2000
Maleimide), 1,2-dipalmitoyl-sn-glycero-
3-phosphoethanolamine-N- (7-nitro-2-1,3 benzoxadiazol- 
4-yl) (NBD-PE), phosphatidylethanolamine dioleoyl- 
sulforhodamine B (Rho-PE) were purchased from Avanti 
Polar Lipid Inc. (Alabaster, AL, USA) and Nucleopore® Track-
etched membranes were purchased from Whatman (Maid-
stone, UK). The study protocols were approved by the Erasmus 
MC Institutional Ethical Committee, the Netherlands.
Preparation, purification, and 
characterization of scFv
scFv G8 and Hyb3 were produced as Fab fragments by 
Willemsen et al5 by using phage display library, a technique 
that employs bacteriophages to study protein–protein inter-
actions and connect the proteins to genetic information that 
encodes them. Fab fragments were reformatted into scFv 
for targeting T-cells to M1/A1 cells.5,28,29 scFv-DNAs were 
excised from pBullet vector via the restriction sites SfiI and 
NotI and cloned into pABC4 vector,31 derived from pAB1. 
The MYC tag was removed and an additional cysteine code 
was added behind the histidine tag.31 Upon protein produc-
tion, the two tags are produced as part of the scFv at the 
C-terminus. The histidine tag was used to purify scFv from 
the periplasmic fraction (pf)32 of BL21 bacteria. The pf was 
subjected to IMAC33 over Ni2+ column. Briefly, all the pro-
teins that hold a histidine tag have affinity for Ni2+ ions and 
hence get adsorbed in the agarose gel matrix.
Various optimization steps were carried out to obtain the 
protein, including 1) using three different strains of E coli 
bacteria including TG1, HB2151, and BL21, 2) growth at 
37°C preinduction and utilization of different temperatures 
(30°C, 35°C and 37°C) postinduction, and 3) conditions such 
as duration of time after induction (4 hours or overnight). 
In addition to these parameters, cell compartments such as 
supernatant, pf, and cytoplasmic fractions (cfs) were analyzed 
to detect protein content. In previous studies, Messerschmidt 
et al34 and Baum et al35 used pABC4 vector in combination 
with TG1 bacteria to produce scFv by growing for 3 hours 
post induction at room temperature (23°C).36
Protein was produced as described previously by Ruger 
et al.36 Briefly, bacteria were grown in cultures at 37°C for 
2.5 hours until an optical density of 0.6–0.8 was reached at 
600 nm. Cultures were then induced with 1 mM isopropyl 
β-d-1-thiogalactopyranoside (IPTG) and grown at 37°C for 
an additional 4 hours. Cultures were pelleted at 4,500× g for 
10 minutes at 4°C and frozen until further use. Pellets were 
thawed and resuspended in ice-cold periplasmic preparation 
buffer (30 mM tris-HCl, 20% sucrose, and 1 mM EDTA 
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[pH 7]).36,37 The cells were lysed with 50 µg/mL lysozyme,37 
and the spheroblasts were stabilized with 5 mM MgSO
4
. 
Samples were centrifuged at 10,000× g for 15 minutes 
at 4°C, and supernatants were collected, respun, and passed 
over 0.45 µm filters. Upon production of the protein, six 
histidine molecules and a cysteine molecule were present 
at the C-terminus. The histidine tag was used for purifica-
tion of the molecule via IMAC, while cysteine was used for 
coupling to liposomes later. Proteins were purified by IMAC 
on AKTA system by using Ni+2 columns. Sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) was 
done to determine the monomer of the produced protein and 
assess its purity. Concentration was determined either by 
Nanodrop® (Thermo Scientific) by measuring the absorbance 
at 280 nm or by using protein assays like Bicinchoninic acid 
Assay (BCA) and Bradford assay. Fractions with scFv protein 
were concentrated over Amicon filters (MWCO 10 kDa; 
Millipore) and kept at 4°C until further use.
cell cultures
Four patient derived melanoma cell lines were used of which 
two cell lines, MZ2Mel43 and G43, are M1/A1positive and two 
cell lines, Mel78 and Mel2A, are M1negative but HLA-A1positive 
(Figure S1). Tumor cells were maintained in Dulbecco’s Mod-
ified Eagle’s Medium (Invitrogen) supplemented with 10% 
fetal bovine serum, nonessential amino acids, l-glutamine and 
penicillin–streptavidin solution. APD cells,6,8,38,39 which are an 
Epstein-Barr virus-transfected immortalized B-lymphoblast 
cell line, are HLA-A1positive. They were maintained in RPMI-
1640 medium supplemented with 10% fetal bovine serum, 
l-glutamine and penicillin–streptavidin solution. All cells 
were maintained at 37°C/5% CO
2 
in a humidified incubator. 
Cells were passaged upon reaching 80%–90% confluency. 
All the media had phenol red as a pH indicator.
In vitro binding of scFv
One of the steps in characterizing these scFvs was to evaluate 
their binding to APD cells and native tumor cells. APD cells 
were cultured in suspension at 500,000 cells per sample and 
pulsed with MAGE A1 peptide (10 µg/mL) for 30 minutes 
at 37°C. Cells were then subjected to a centrifugation at 
450× g for 5 minutes, medium was aspirated, and various 
scFv concentrations ranging from 0.1 to 100 µg/mL in a 
volume of 200 µL were added to the cells for 1 hour at 4°C. 
For 500,000 tumor cells per sample, a concentration of 50 
and 100 µg/mL of scFv was chosen to be incubated for 
1 hour at 4°C. Cells were washed with 2 mL of ice-cold PBS 
once and incubated for 1 hour at 4°C with anti-HIS antibody 
(1:20) and then incubated with goat-anti-mouse PE antibody 
(1:500) for 1 hour at 4°C. Finally, cells were incubated for 
10 minutes at room temperature with 10 µL of 7AAD per 
sample to exclude dead cells. Cells were washed with 2 mL 
ice-cold PBS and were either measured in 250 µL PBS or 
fixed in 250 µL of 1% PFA until measured. All samples were 
measured on BD FACS Canto™ (Becton, Dickinson Com-
pany, Franklin Lakes, NJ, USA) with BD FACS Diva soft-
ware (San Jose, CA, USA) and analyzed using FCS Express 
(De Novo Software, Los Angeles, CA, USA). Phage-Hyb3 
was used as a control and detected using anti-M13 antibody 
(1:500) and a secondary goat-anti-mouse PE.
Preparation and characterization of 
liposomes
A neutral liposome composition was chosen for this 
research; typically HSPC, cholesterol, DSPE-PEG
2000
, and 
maleimide-PEG
2000
 were used in a molar ratio 55:40:4:1.31,40 
Liposomes were prepared by film hydration method as pre-
viously described.34,37,41,42 Briefly, all lipids were mixed in a 
round bottom flask and dissolved in chloroform:methanol 
(9:1 v/v). A thin and uniform lipid film was obtained by 
evaporating the solvents under pressure for 30 minutes 
at 42°C. This film was then flushed for 20 minutes under 
nitrogen and hydrated with 10 mM HEPES buffer at pH 6.7 
for 20 minutes at 60°C. If necessary, the film was sonicated 
with silica beads for complete dissolution. The mixture was 
then extruded 17–20 times under pressure through a series 
of polycarbonate filters ranging from 200 to 50 nm to obtain 
a uniform suspension of particles. Size and polydispersity 
index (PDI)31,34,41,43 were determined by dynamic light 
scattering43 on a Zetasizer® Nano ZS (Malvern Instruments, 
Worcestershire, UK). Liposomes were subjected to Rouser 
phosphate assay44 where phospholipid was determined and a 
total lipid amount was calculated after cholesterol correction. 
For experiments, 0.3% Rhodamine-PE or 0.3% NBD-PE was 
used as fluorescent probe in either formulation.
Immunoliposome formulation and 
characterization
Immunoliposomes were produced by postattachment method 
of coupling,18,45 also known as conventional coupling, to 
maleimide-PEG liposomes.36,37 Fresh, preformed liposomes 
were incubated with prereduced scFv. ScFvs were reduced 
using TCEP (10 mM at a final concentration)34,37 under N
2
 at 
room temperature for 1 hour prior to the coupling. We found 
that reduction of scFv was a necessary step, as we observed 
greatly reduced binding without reduction, although the 
majority of scFv was present as monomer (data not shown). 
TCEP was removed from the mixture by washing five times 
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with deoxygenated coupling buffer (10 mM Na
2
HPO
4
/
NaH
2
PO
4
 buffer, 0.2 mM EDTA, 30 mM NaCl [pH 6.7]) 
and concentrating at the same time over Amicon filter 
(MWCO 10 kDa, Millipore) for 10 minutes, after each wash 
step, at 4,000× g and 4°C. Final concentration was deter-
mined using Nanodrop®. An amount of 340 µg of scFv was 
mixed with 10 µmol of freshly made liposomes for a total 
of 16 hours. The mixture was overlaid by N
2
 and left on a 
shaker incubator for 2 hours at room temperature and then 
overnight at 4°C without shaking. After 16 hours of total 
coupling, free maleimide groups were quenched with 1 mM 
L-cysteine31,34,36,37,42 for 10 minutes at room temperature, and 
uncoupled scFv was removed by gel filtration over Sepharose 
CL4B (retailer) column (GE Healthcare),34,36,37,42 pretreated 
with 10 mM HEPES buffer pH 7.4. The immunoliposomes 
obtained were subjected to phospholipid determination once 
more and the total protein coupled was determined by Lowry–
Peterson assay.46 The number of scFv molecules attached was 
calculated using the protein and lipid determinations. Size 
and charge was determined on the Zetasizer®.
elIsa
A concentration range of 1–100 µg/mL of free scFv and 0.05 
to 1 µM of total lipids was tested on ELISA (enzyme-linked 
immunosorbent assay). Briefly, Nunc 96 (Sanbio, Mountain 
View, CA, USA) flat well plates with streptavidin coating 
were washed three times with 0.1% Tween-PBS and twice 
with PBS and incubated with biotinylated M1/A1 complex 
(1 µM) for 30 minutes at room temperature or overnight at 
4°C. All further steps were carried out at room temperature. 
Wells were blocked with 2% milk–PBS for 30 minutes. 
Dilutions of free scFv and immunoliposomes were made in 
4% milk-PBS in 100 µL volume and incubated for 1.5 hours 
in each well after which wells were washed. Anti his-HRP 
antibody was diluted in 2% milk-PBS, added to the wells, 
and incubated for 1 hour. Wells were subsequently washed 
with PBS and 0.1% Tween-PBS and supplemented with 
ELISA substrate. The reaction was stopped with 1 M H
2
SO
4
. 
As control, w6/32 antibody was used, which only showed 
a positive signal if the M1/A1 complex bound to the plate 
successfully. HRP conjugated anti-His tag antibody was used 
to recognize the His tag on scFv, and substrate development 
was read with a TECAN ELISA reader (BioTek, Winooski, 
VT, USA).
In vitro binding of immunoliposomes
APD cells were cultured in suspension at 500,000 cells per 
mL and pulsed with MAGE A1 peptide (1 µM) for 30 minutes 
at 37°C. Cells were then subjected to centrifugation at 450× g 
for 5 minutes, medium was aspirated, and liposomes were 
added to the cells. A range of concentrations from 0.05 µM 
to 1 µM total lipid in a volume of 200 µL was added for 
1 and 2 hours at 4°C and 37°C. For tumor cells, a concen-
tration of 0.5 µM and 1 µM (total lipid) was chosen to be 
incubated for 1 and 2 hours at 4°C and 37°C. These cells 
were washed with ice-cold PBS and incubated for 10 minutes 
at room temperature with 7AAD to exclude dead cells. 
Cells were again washed with ice-cold PBS and were either 
measured in PBS or fixed in 1% PFA. All samples were 
measured on BD FACS Canto with BD FACS Diva software 
and analyzed by FCS express software.
confocal microscopy
For confocal microscopy, liposomes were formulated with 
Rhodamine PE (λ
ex
 560 nm, λ
em
 583 nm). Glass cover 
slips (25 mm diameter) were coated with either 500 µL 
of 0.1% collagen37 or 0.1% gelatin for 30 minutes at 37°C 
and washed with sterile PBS. Tumor cells were harvested 
and grown on the coated cover slips at a concentration 
of 0.5×106 in 6-well plates overnight at 37°C in 5% CO
2
. 
Next day, cells were incubated with immunoliposomes 
at a concentration of 1 µM (total lipid) for 2 hours at 
37°C, carefully washed with ice-cold PBS, and overlaid 
with medium at 37°C until they were imaged. Cells were 
imaged with confocal microscope (Zeiss LSM 510 META, 
Zeiss, Jena, Germany) with a 40× oil objective lens (NA 
1.3) using a 543 nm helium–neon laser and 560–615 
band pass filter. Images were analyzed with LSM Image 
browser (Zeiss).
statistical analysis
ELISA readings were analyzed using Graphpad Prism 
software (La Jolla, CA, USA). All data was analyzed using 
Kruskal–Wallis and Mann–Whitney U tests. Data was pro-
cessed using GraphPad Prism and SPSS software (version 
21) (IBM Corporation, Armonk, NY, USA).
Results
Optimized production of cys-containing 
and M1:a1-binding scFv
The first step toward obtaining specific immunoliposomes was 
to produce TCR-mimicking scFv. An additional cysteine group 
was required at the 3′ end of scFv to facilitate site-directed 
coupling to liposomes.31,34 As reported by Messerschmidt 
et al,31 pABC4 vector, derived from pAB1 vector, adds a 3′ 
cysteine group to scFv inserts, followed by a His tag to enable 
protein purification.31 Various optimization steps were carried 
out to successfully produce scFv molecules. The parameters 
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optimized for scFv production included: 1) bacterial strains, 
2) duration of bacterial growth, 3) temperature after protein 
induction, and 4) type of cellular compartments. Bacte-
rial cultures were induced with IPTG and grown either at 
30°C, 35°C or 37°C for 4 hours or overnight. We observed 
an increase in total protein production when bacteria were 
grown at 37°C for 4 hours. Bacterial strains included TG1, 
HB2151, and BL21, and pfs of 4 hours cultures of BL21 at 
37°C proved to be most optimal with respect to yield of scFv 
(Figure 1A). The two compartments checked for protein were 
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Figure 1 Optimization of bacterial culture conditions for scFv production.
Notes: (A) Production of proteins hyb3 and g8. (i) Bl21, hB2151, or Tg1 bacterial cultures were grown to obtain scFv hyb3, which were analyzed by sDs-Page and 
subsequent immunostaining on Western blot; cf, pf, D3 is a Fab fragment reduced and run in parallel as a positive control. 1) D3, positive control, 2) Bl21 cf, 3) Bl21 pf, 4) Tg1 
cf, 5) Tg1 pf, 6) hB2151 cf at 30°c, 7) hB2151 pf at 30°c, 8) hB2151 cf, 9) hB2151 pf and protein marker. (ii) Bl21 and hB2151 bacteria used for production of g8 and hyb3 
at 37°c. 1) D3, positive control, 2–4) Bl21 produced scFv g8 pf, 5–7) Bl21 produced scFv hyb3 pf, 8, 9) hB2151 produced scFv hyb3 pf and protein marker. (B) Purification of 
scFv G8 and scFv Hyb3 proteins by IMAC. Chromatogram showing purification of BL21-derived scFv Hyb3 from pf at 37°c 4 hours of growth, postinduction. Blue line is protein 
absorbance measured at 280 nm. First part of chromatogram is the flow through defined as all protein not bound to Ni2+ column. green line is Imidazole gradient used to elute 
the bound protein of interest. Peak after green line is the scFv of interest. The insets show the results of the SDS-PAGE and Western blot analyses of purity and size of purified 
scFv proteins. Fractions 7 and 8 consist of the peak fractions from the chromatogram and were run on sDs-Page and subjected by Western blot using anti-hIs mab hrP.
Abbreviations: scFv, single-chain variable fragment; cf, cytoplasmic fraction; pf, periplasmic fraction; IMAC, immobilized metal ion affinity chromatography; SDS-PAGE, 
sodium dodecyl sulfate-polyacrylamide gel electrophoresis; hrP, horseradish peroxidase; Fr, protein fraction from IMac on gel.
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the pf and cf, where the pf contained the highest protein yield, 
which was also reported in previous studies.34 pf and cf were 
run on gel and subsequently assessed by immune staining. 
A comparison of Hyb3-containing fractions from three 
bacterial strains grown under similar conditions, pre- and 
postinduction at 37°C for 4 hours show a dense band depict-
ing higher yield (Figure 1A [i]) from the pf of BL21 bacterial 
culture. Protein content reached up to 1 mg per liter of BL21 
bacterial culture in comparison with a ~250 µg protein yield 
from HB2151, while there was negligible amount of protein 
in TG1 cultures (~120 µg). The yield of scFv G8 in the pf of 
BL21 bacteria grown at 37°C post induction for 4 hours was 
comparable to Hyb3 production as shown in Figure 1A (ii) 
on 14% bis-Tris SDS gel.
Chromatography resulted in good separation, and a single 
band was detected on SDS-PAGE in the form of a monomer 
at a molecular mass of 27 kDa (Figure 1B). Collected frac-
tions were pooled, concentrated, and tested for their binding 
to EBV-transformed B-cells (APD) before proceeding with 
their coupling to liposomes. B-cells have a high expression of 
HLA-A1 surface molecules,47 and when pulsed with MAGE 
A1 peptide (EADPTGHSY), they are recognized by Fab-Hyb3 
and G8 as positive targets.28,29 Hyb3 and G8, following their 
reformatting into scFv and used at a concentration of 10 µg/
mL, bound readily to APD cells pulsed with peptide MAGE 
A1 (Figure 2A). As a positive control, Phage Hyb3 was used. 
All cells were gated on their respective control, and APD 
cells without peptide were used as a negative control showing 
almost no binding of scFvs. A complete shift in the histogram 
toward the right indicates that the complete population of APD 
cells interacted with scFvs. At the different concentrations 
tested, scFv G8 and Hyb3 demonstrated comparable binding 
to APD cells pulsed with peptide. However, Hyb3 showed a 
trend toward better binding and specificity toward these cells 
(Figure 2B). Binding of scFv Hyb3 at lower concentrations is 
attributed to its affinity maturation and hence higher affinity 
and sensitivity to recognize the peptide:MHC (pMHC).28 Once 
scFvs passed this validation, they were subjected to reduction 
with TCEP, to guarantee efficient availability of the cysteine 
sulfhydryl, prior to coupling to liposomes.
Optimized generation of scFv-coupled 
immunoliposomes and their binding to 
M1:a1
Liposomes were composed of neutral lipids31,34,35,42 as shown 
in Table 1, and all formulations were made by the lipid film 
hydration method.48 Liposomal parameters such as size, PDI, 
and surface charge were determined. When within-set criteria 
was size between 80±5 nm before coupling, PDI below 0.1, 
and surface charge between -12 and -16 mV, liposomes were 
used for coupling. Initial immunoliposome validations with 
flow cytometry were done using NBD-PE (0.3%) anchored 
in the lipid bilayer to determine fluorescence of liposomes 
after binding to cells. Size of particles was also measured 
post coupling, and immunoliposomes were only used for 
subsequent experiments when each batch met the set crite-
ria previously mentioned, but with a size range between 80 
and 95 nm. Table 1 summarizes three independent batches 
of immunoliposomes as an example before and after the 
coupling out of 16 batches that met the criteria.
The generation of immunoliposomes was based on site-
directed coupling of scFvs via their C-terminal cysteines to 
maleimide on the outer end of the PEG molecule. Immu-
noliposomes were reduced with β-mercaptoethanol and 
gel-analyzed to determine size change31 before and after 
coupling36 (Figure 3A). The actual molecular weight of scFv 
was around 27 kDa; however, after coupling we observed 
the expected shift to 30 kDa due to attachment of the 3 kDa 
PEG molecule.31,49 Size change of the scFv after coupling 
was confirmed by dynamic light scattering, which showed an 
acceptable increase in the liposome size (around 10 nm) and 
PDI (Table 1). Quantification of total lipid and protein levels 
of immunoliposomes resulted in a calculated assessment of the 
number of scFv (G8 and Hyb3) molecules to be between 13 and 
23 per liposomes. For APD binding and confocal experiments, 
liposomes-scFv G8 (L-scFv G8) had 18, 19 and 21 molecules 
per liposome and liposomes-scFv Hyb3 (L-scFv Hyb3) had 
22, 23 and 20 molecules, whereas for tumor cells binding and 
confocal experiments L-scFv G8 had 13 and 18 molecules 
per liposomes and L-scFv Hyb3 had 15 and 22. ELISA was 
performed for all batches. Batches which had a similar coupling 
efficiency and number of post coupling molecules of scFv per 
carrier, were selected for further experiments. After coupling, 
immunoliposomes were stored in 10 mM HEPES pH 7.4 buffer, 
under N
2
 (vacuum), at 4°C in the dark. Postcoupling liposome 
sizes and PDI did not change in 2 weeks (Table S1).
Immunoliposomes were further subjected to ELISA 
(Figure 3B). The main aim of testing liposomes-scFv on 
ELISA was to show whether scFvs remains functional after 
coupling. It has been observed that certain nanobodies lost 
functionality after they were coupled with liposomes. Also, 
it has been reported that PEG molecules can form a mush-
room like structure which may cover the antigen binding 
domain and affect the biological function of scFv molecules. 
With the ELISA, we prove that scFv remain functional 
postcoupling to liposomes and bind to immobilized pMHC. 
A concentration from 0.05 µM to 1 µM based on total lipids 
shows an increasing signal on ELISA, which was then used 
International Journal of Nanomedicine 2016:11submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
962
saeed et al
to determine a suitable concentration to be used in later 
experiments. We assessed immunoliposomes binding to 
immobilized M1/A1 complexes covalently bound to ELISA 
plates. Nontargeted conventional liposomes show almost 
no binding, whereas immunoliposomes showed significant 
and liposome concentration-dependent binding (Figure 3B). 
Notably, L-scFv Hyb3 showed improved binding compared 
to L-scFv G8, (P,0.001) indicating a significant difference 
between the two targeted formulations (Figure 3B). Free 
scFvs were also tested for pMHC recognition on ELISA. 
A concentration-related binding was observed, indicating 
specific and increased binding to pMHC. However, when 
Figure 2 scFv G8 and Hyb3 specifically recognize M1/A1 on cells.
Notes: Flow cytometry of hla-a1+ B cells (aPD) with or without Mage a1 peptide with scFv g8 or hyb3. (A) histograms showing binding of scFv g8 and hyb3 at 
a concentration of 10 µg/mL to APD cells pulsed with peptide MAGE A1. Phage Hyb3 (purple) were used as a positive control for binding to APD cells, APD + peptide 
incubated with scFv g8 at a concentration of 10 µg/mL (red), APD + peptide incubated with scFv hyb3 at a concentration of 10 µg/mL (green), and the solid line represents 
aPD cells without peptide as a control. (B) Binding of scFv g8 and hyb3 at concentrations ranging from 0.1 to 10 µg/mL to APD cells. The data are represented as mean 
of n=3 with standard deviation. *P,0.05.
Abbreviations: scFv, single-chain variable fragment; M1/A1, MAGE A1 presented by HLA-A1; MAGE A1, Melanoma AntiGEn A1; HLA-A1, human leukocyte antigen A1.
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compared with liposomal scFv, it was negligible, thus 
showing that liposomal scFv is a more sensitive system in 
recognizing pMHC complexes. No significant differences 
were found among free scFvs (Figure 3C).
Following these validations, immunoliposomes were 
tested for their in vitro binding to cells. To this end, they were 
incubated with APD cells pulsed with MAGE A1 peptide. 
Flow cytometry revealed minimal binding of nontargeted 
liposomes (6%), whereas targeted immunoliposomes (L-scFv 
Hyb3 70%, L-scFv G8 84%) bound to a greater extent at 4°C 
after 1 and 2 hours (Figure 4A and B).
When liposome-scFv Hyb3 was used, binding to APD 
control cells (APD cells without the M1 peptide) was observed 
at 4°C and 37°C after 1 or 2 hours, which we designated 
Table 1 composition, measurements of sizes, and PDIs
HSPC Cholesterol DSPE-PEG2000 Maleimide-PEG2000 Rhodamine-PE
55 40 4 1 0.3
Before coupling size average 80 nm and PDI ,0.1
Batch 1 Batch 2 Batch 3
Size (nm)a PDIb Size (nm) PDI Size (nm) PDI
liposomes 80.34 0.048 81.80 0.065 79.30 0.011
liposomes-scFv g8 93.62 0.072 91.46 0.085 84.32 0.014
liposomes-scFv hyb3 94.77 0.078 91.23 0.081 93.67 0.096
Notes: asize of the immunoliposomes postcoupling was set to be 85±10 nm. ba PDI of zero means that population is homogeneous, whereas a PDI of 1 means a 
nonhomogeneous population; for this study, a PDI of below 0.1 was considered acceptable. Three independent batch characterizations regarding size and PDI measurements 
of the immunoliposomes postcoupling.
Abbreviations: scFv, single-chain variable fragment; PDI, polydispersity index; hsPc, hydrogenated soy l-α-phosphatidylcholine; DsPe-Peg2000, 1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N-Peg2000; Maleimide-Peg2000, 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-26; rhodamine-Pe, phosphatidylethanolamine dioleoyl-sulforhod amine B.
Figure 3 Validation of immunoliposomes postcoupling by sDs-Page and elIsa.
Notes: (A) Denatured sDs-Page gel analysis showing liposomes postcoupling, 1) scFv hyb3 precoupling, 2) liposomes-scFv hyb3 postcoupling, 3) control liposomes, 
4) protein marker, 5) control liposomes, 6) scFv g8 pre-coupling, 7) liposomes-scFv g8 postcoupling. (B) Binding of liposomes-scFv G8 and Hyb3 to immobilized M1/A1 
peptide on elIsa to assess the postcoupling activity of scFvs. Data represents n=6 for liposomes and liposomes-scFv g8 and n=3 for liposomes-scFv hyb3 with a P-value ,0.005 
among liposomes and hyb3 at all concentrations. *P,0.05 for liposomes and liposomes-scFv g8. #P,0.005 for l-scFv g8 and l-scFv hyb3. (C) Binding of scFv g8 and hyb3 
to immobilized M1/A1 peptide on ELISA before coupling. Data represents n=6 in triplicate with four independent batches. There is no significant difference among the two 
antibodies toward peptide recognition. P-value ,0.001 in comparison with control.
Abbreviations: sDs-Page, sodium dodecyl sulfate-polyacrylamide gel electrophoresis; elIsa, enzyme-linked immunosorbent assay; scFv, single-chain variable fragment; 
M1/A1, MAGE A1 presented by HLA-A1; MAGE A1, Melanoma AntiGEn A1; HLA-A1, human leukocyte antigen A1.
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Figure 4 Binding of immunoliposomes to aPD cells.
Notes: Flow cytometry analysis showing binding of nontargeted liposomes, liposomes-scFv g8 and hyb3 to aPD cells. (A) Binding of liposomes-scFv g8 and hyb3 at a 
concentration of 1 µM (total lipid) at 4°c and 37°c for 1 and 2 hours. This data is a representation of n=4 with P,0.05 between nontargeted liposomes and immunoliposomes 
bound to aPD + M1 cells. (B) histograms showing binding of liposomes to aPD + M1 cells at a concentration of 1 µM (total lipid) at 4°c 2 hours as an example, blue: 
nontargeted liposomes bound to aPD + M1 cells, green: liposomes-scFv hyb3 and red: liposomes-scFv g8 bound to aPD + M1 cells. The solid black line represents unstained 
aPD – M1 cells as background. (C) confocal images of aPD cells (500,000 cells per ml) pulsed with peptide and incubated with immunoliposomes for 2 hours at 37°c. 
as compared to nontargeted liposomes, immunoliposomes show much higher binding to aPD cells, i) unstained aPD cells-M1, ii) aPD – M1: liposomes, iii) aPD + M1: 
liposomes, iv) aPD – M1: liposomes-scFv g8, v) aPD + M1: liposomes-scFv g8, vi) aPD – M1: liposomes-scFv hyb3, vii) aPD + M1: liposomes-scFv hyb3.
Abbreviation: scFv, single-chain variable fragment.
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off-target binding (Figure S2). This binding (56%) was not 
as profound as when the peptide M1 was added (100%), but 
was higher than binding of control liposomes or cell only 
(5%) (Figure 4B, Figure S2). When liposome-scFv G8 was 
added to APD cells without peptide M1, these APD cells 
remained negative (9%) when compared to experiments using 
nontargeted liposomes or cells only (5%). Addition of the 
M1 peptide to APD cells resulted in specific binding of the 
liposome-scFv G8 (97%). It is hypothesized that this off-
target binding of L-scFv Hyb3 to antigen-positive B-cells 
may be attributed to affinity maturation of scFv Hyb3.
We subsequently investigated cellular internalization 
of fluorescently-labeled immunoliposomes by confocal 
microscopy. These experiments demonstrated that immuno-
liposomes are distributed on the surface of antigen-positive 
B-cells (Figure 4C), and some surface distribution was also 
seen on antigen-negative cells, which is in line with our 
flow cytometric data (Figure 4A). Minimal binding to APD 
cells was also observed with nontargeted liposomes. The 
3D projection of these cells confirms surface distribution of 
immunoliposomes (Video S1 and S2). Binding of immuno-
liposomes to APD cells was observed but internalization was 
not evident in agreement with reports by others. Mommaas 
et al,47 showed that B-cells present antigen but there is no 
antigen mediated uptake by these cells which suggest B-cells 
do not internalize through MHC class I molecule.50 Also, 
the present study suggests that there is no MHC-mediated 
endocytosis in B-cells when incubated with scFv-coupled 
liposomes. As discussed earlier, L-scFv Hyb3 show some off-
target binding with APD cells without peptide (Figure 4C); 
however, positive cells show higher signal in accordance 
with our flow cytometry data (Figure 4A). From ELISA and 
flow cytometry results, we concluded that activity of scFv 
after coupling to liposomes was preserved up to 1 week of 
storage (Figure S3).
scFv-coupled immunoliposomes 
specifically target and are internalized by 
M1/A1-positive melanoma cells
Following experiments with antigen-high APD cells, we 
studied in vitro binding of immunoliposomes to antigen-low 
tumor cells, which included two M1/A1-positive and two 
negative cell lines (assessed for MAGE A1 and HLA-A1 
expression by polymerase chain reaction (Figure S1). The 
flow cytometric binding experiments were conducted at 
4°C and 37°C for 1 and 2 hours. Minimal binding was seen 
with nontargeted liposomes to all cell lines, however L-scFv 
Hyb3 bound 8 times greater to melanoma cells MZ2Mel43 
and G43 (Figure 5A and B), while binding was much lower 
to negative melanoma cells Mel78 and Mel2A. The results 
also demonstrate that L-scFv Hyb3 showed (in contrast to 
findings with APD cells) improved binding compared to 
L-scFv G8, most likely due to the more physiological low 
surface expression of antigen on melanoma cells. Again, 
some off-target recognition was observed using antigen-
negative melanoma with L-scFv Hyb3. Strikingly, binding 
at 37°C was greatly reduced in antigen-positive melanoma 
cell lines for both immunoliposomes (~6 times lower), which 
we attribute to the internalization and processing of these 
immunoliposomes as shown in Figure 5C.
To complete our analysis, immunoliposomes were 
further tested on melanoma cells and imaged with confocal 
microscopy to visualize binding and internalization at 37°C 
for 2 hours (Figure 5C). M1/A1-positive melanoma cells 
Figure 5 (Continued)






°&KRXUV°&KRXU°&KRXUV°&KRXU
R
IOLS
RVR
PHV
ERX
QGW
R
0=
0HO
F
HOOV
 
 
 







°&KRXUV°&KRXU°&KRXUV°&KRXU
R
IOLS
RVR
PHV
ERX
QGW
R*

FHOO
V


 

 
L LL$
/LSRVRPHVVF)Y+\E/LSRVRPHVVF)Y*/LSRVRPHV
International Journal of Nanomedicine 2016:11submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
966
saeed et al
Figure 5 (Continued)
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internalized L-scFv Hyb3 and L-scFv G8 rapidly, while 
internalization by M1/A1-negative melanoma cells was 
negligible (Figure 5C), corresponding with the flow cytom-
etry results. Moreover, M1/A1-negative melanoma cells 
hardly bound nor internalized both nontargeted liposomes 
as well as L-scFv Hyb3 and L-scFv G8.
Discussion
Several antibody-mediated immunotherapies are in develop-
ment or already approved. In spite of the relative success, 
most patients with metastasized melanoma do not respond 
to therapy or will progress under treatment. Therefore, it 
is essential that new therapies are developed, which need 
to be specific, can be dosed repeatedly, and have as little 
side effect as possible. A highly specific process is TCR-
mediated targeting of cancer cells. Previously, we showed 
specific targeting with TCR-engineered T-cells using G8 Fab 
fragment to M1/A1-positive melanoma cells, which induces 
antigen-specific killing of melanoma cells.5 These T-cells 
were capable of inducing cytokine production, such as TNFα, 
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Figure 5 In vitro binding and internalization of immunoliposomes by tumor cells.
Notes: (A) Flow cytometry analysis showing binding and partial internalization of immunoliposomes by tumor cell lines. This data is a representation of n=4. (i) MZ2Mel43 (+), 
(ii) g43 (+), (iii) Mel78 (-), and (iv) Mel2a (-). *P,0.05. (B) histograms of all cell lines at 4°c for 2 hours showing binding of liposomes and immunoliposomes. Blue: 
nontargeted liposomes, green: liposomes-scFv hyb3 bound cells, and red: cells bound with liposomes-scFv g8. The solid line represents unstained cells for each cell line. 
Upper row represents both positive cell lines and lower row shows the negative cell lines. (C) confocal images of positive and negative cell lines after incubating with 
immunoliposomes for 2 hours at 37°c.
Abbreviation: scFv, single-chain variable fragment.
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IL-2, and INFγ, in targeted cells. A study by Willemsen et al5 
showed the successful production of MHC Class I specific 
T-cells grafted with TCR αβ after retroviral transduction. 
Although forced preferred pairing of the TCR, to prevent 
unwanted mispairing, provides a strategy to increase efficacy 
and safety of retargeted T-cells,6 using a mimicking antibody 
solves TCR mismatch and potential self-reactivity. Using 
the TCR as a model, we proposed to decorate liposomes 
with TCR-mimicking scFv to target melanoma cells. This 
introduces the possibility of establishing a clean and tunable 
system for therapy.
In this study, we show that novel TCR-like scFvs, and 
the high- and low-affinity Hyb3 and G8 specific for M1/A1, 
were successfully produced, characterized, and coupled to 
nanoparticles, ie, liposomes, to produce targetable devices, 
also called immunoliposomes, that allow in vitro targeting 
of antigen-low melanoma cells. To acquire scFv-based 
immunoliposomes which are of consistent quality and 
display specific binding, the production of scFv had to be 
optimized by testing several bacterial strains, growth time, 
temperature postinduction, and bacterial compartments to 
yield a better quality and quantity protein. Finally, the pf of 
BL21 bacteria was used for protein production at 37°C for 
4 hours to obtain both proteins. Previously, production of 
scFv by growing bacterial culture at room temperature (23°C) 
for 3 hours postinduction has been described, while others 
used the pABC4 vector, but the same conditions to produce 
scFv.35 Importantly, our optimization results in a better yield 
of the antibodies using pABC4 vector in combination with 
BL21 bacteria and growing cultures at 37°C for 4 hours.
As reported in previous studies, scFv molecules retain 
complete antigen binding while the Fc domain is missing. 
Removal of the Fc domain renders these fragments less 
immunogenic, and no Fc receptor-mediated signaling and 
complement activation occurs. Previous studies demonstrated 
that interaction of macrophages with whole mAb coupled to 
liposomes is Fc domain mediated.51 Likewise, Kupffer cells 
in vitro interact with antibody decorated liposomes through 
the Fc domain. Uptake of these liposomes is shown to be less 
when mAb are coupled via the Fc domain to liposomes, which 
shields recognition somewhat, indicating its involvement in 
uptake.52 Fc receptor coupling to liposomes favors binding 
to tumor cells but does not exclude the recognition by mac-
rophages. Cheng and Allen53 compared liposomes coupled 
with whole antibody or with scFv against B-cell antigen 
CD-19. They show that mAb-liposomes were cleared rapidly 
from the bloodstream due to Fc receptor-mediated uptake, 
while circulation time of scFv-liposomes was prolonged.
Since scFvs are less stable than whole antibodies19 or Fab 
fragments, freshly prepared scFvs were used to form immu-
noliposomes. The scFv produced were tested for their activity 
and then coupled to preformed liposomes, and coupling was 
considered successful when they conformed to strict valida-
tion criteria. Immunoliposomes made by conventional meth-
ods have limitations.36,42,45 In particular, antibodies or scFv 
molecules may randomly bind with liposomal maleimide, 
and the true number of scFv per carrier cannot be accurately 
determined. We set strict validation criteria in terms of size, 
PDI, quantity of lipids, protein, and activity of scFv using easy 
readouts to minimize errors in calculating the number of scFv 
molecules per liposome and thereby minimizing batch-to-batch 
variation. Total lipid and protein concentration was determined, 
and the number of scFv molecules coupled to the liposomes was 
calculated. As a final validation step, immunoliposomes were 
tested for binding of M1/A1 complexes by ELISA. Only those 
batches that met the above stated criteria were used for subse-
quent experimentation, taking into account further therapeutic 
use. A schematic presentation of our conjugation, production, 
and the criteria used for analysis is shown in Figure 6. After 
coupling, the scFvs still remained functional, which was proven 
by ELISA and flow cytometry. It was important to determine 
the functionality of these scFv after coupling, before proceed-
ing to further advanced experiments. It has been reported in 
literature that coupling of scFv to maleimide groups can result 
in a shielding effect where scFv cannot access antigen due to 
PEG molecules forming a mushroom-like barrier54 and hinder-
ing interaction with antigens.30 Here, we show via a simple 
ELISA assay that it can be determined whether or not scFvs 
are functional after coupling.
Importantly, we observed that immunoliposomes showed 
specific and significant binding to peptide-pulsed APD cells, 
whereas negligible binding occurred to peptide-negative cells. 
There was no internalization observed in APD cells, which 
corresponds with a study by Mommaas et al47 where they 
incubated APD cells and (antigen stimulated) T-cells with 
endorphin gold and observed only binding in APD cells and 
uptake in T-cells, indicating that APD cells do not internalize 
MHC class I molecules. We also showed immunoliposome 
binding to antigen-positive melanoma cells in comparison 
with negligible binding to antigen-negative melanoma cells 
at 4°C, whereas internalization occurred at 37°C as deter-
mined by flow cytometry and confocal microscopy. Binding 
to tumor cells depends on many factors, such as the ligand-
binding affinity of the scFv used, density of scFv on the 
carriers, and quantity of pMHC on tumor cells.30 Binding and 
internalization of liposomes is expected to be more efficient 
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as multiple binding sites are available, increasing the avidity, 
as compared to single scFv. Uptake is dependent on targeted 
moieties on the cell membrane, while intracellular process-
ing of liposomes is also dependent on the physicochemical 
properties of the liposome. In spite of low expression of 
pMHC on tumor cells when compared to peptide-pulsed 
B-cells, we see pronounced and significant binding of 
immunoliposomes by tumor cells, which was followed by 
internalization. Here, we have generated two recombinant 
scFvs, which we have used to couple to liposomes: G8 and 
Hyb3. Fab-Hyb3 represents an affinity-matured variant of G8 
Fab, shows preserved fine peptide specificity, and mediates 
an increased T-cell function when constructed into a chi-
meric antigen receptor and transduced into T-cells.29 In the 
same study, antibody genes were displayed on phages and 
phage-Fab-G8 demonstrated binding toward cells pulsed 
Figure 6 schematic presentation of the optimal protocol for generation and validation of Tcr-mimicking immunoliposomes.
Notes: scFv DNa of hyb3 or g8 were transformed into Bl21 bacteria, bacterial cultures were grown at 37°c for 4 hours and followed by IMac to obtain scFv. These 
resulting scFvs were characterized for their purity (by SDS-PAGE) and activity (by flow cytometry) on target-positive cells. Once validated, these scFvs were subjected to 
reduction and then coupled to liposomes. Immunoliposomes formed were also strictly validated through a number of criteria, mainly a size range of 85±5 nm and PDI below 
0.1. Total lipid content was determined along with a total protein content to deduce the number of scFv molecules per liposome. When the number was found to be below 
10, the batch was discarded. elIsa was performed to determine the activity of scFv molecule postcoupling. If the formulation met all the criteria, it was subjected to binding 
and internalization experiments assessed by flow cytometry and confocal microscopy.
Abbreviations: scFv, single-chain variable fragment; IMAC, immobilized metal ion affinity chromatography; SDS-PAGE, sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis; PDI, polydispersity index; elIsa, enzyme-linked immunosorbent assay; Tcr, T-cell receptor.
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with MAGE A1 peptide, which was about two logs less 
compared to phage-Fab-Hyb3. In the present study, we 
produced scFv-G8 and Hyb3 proteins and showed that both 
scFvs, used at a concentration ~10 µg/mL, bind to peptide-
pulsed B-cells, but only the high-affinity scFv-Hyb3 binds 
cells at lower concentrations. Expectedly, liposomes-scFv 
Hyb3 always showed enhanced binding to antigen-positive 
cells compared to liposomes-scFv G8. Of note, however, 
liposome-scFv Hyb3 but not G8 demonstrated off-target 
binding to antigen-negative cells, in particular when using 
antigen-high B-cells, but this was also noticeable when using 
antigen-low melanoma cells. The unwanted off-target bind-
ing mediated by scFv-Hyb3 is most likely caused by its high 
affinity. Interestingly, a study by Mareeva et al55 showed that 
TCR-like antibodies bind to the pMHC recognizing mainly 
its canonical structure based on the interaction of the MHC 
molecule with the peptide. Unlike most TCR-like antibod-
ies however, Fab Hyb3 binds via a noncanonical orientation 
to the pMHC recognizing mainly MHC.56 Complementary 
to these studies, we here demonstrate that liposome-scFv 
Hyb3 not only binds to cells that are M1positive, HLA-A1positive, 
(MZ2Mel43 and G43) but also, however to a low degree, to 
cells that are M1negative, HLA-A1positive (Mel78 and Mel2A). 
In contrast, liposomes-scFv G8 show no off-target binding 
at all and only bound antigen-positive cells; a binding that 
is less when compared to Hyb3, but in all cases specific for 
antigen. Our findings with liposomes-scFv G8 are in exten-
sion to previous studies by our laboratory, which demonstrate 
that Fab G8 protein as well as T-cells transduced with Fab 
G8 bind to M1/A1positive-cells and not HLA-A1positive-cells 
pulsed with peptides that differ from M1 only by a few amino 
acids.5,28 Notably, when gene-engineered T-cells with scFv 
Hyb3 were coupled to costimulatory domains, such peptide 
fine-specificity was lost.38
Another line of evidence pointing to the risk of affinity 
maturation comes from a study by Linette et al,57 which 
demonstrated off-target toxicity in two patients treated 
with T-cells gene-engineered with affinity-enhanced TCRs 
directed against MAGE-A3:HLA-A1. Both patients died due 
to cross-reactivity of T-cells recognizing a striated muscle 
protein called titin, which is highly similar to the targeted 
MAGE-A3 peptide. Other studies have reported that affinity 
enhancement may also result in self-reactivity in T-cells. 
A recent study by Oren et al58 reported that they used a 
high-affinity TCR-like scFv and found that this antibody, 
once transduced into T-cells, resulted in loss of antigen 
specificity, whereas the low-affinity antibody maintained 
T-cell cytotoxic potential and specificity.
However, we used two scFv with different affinities 
to promote interaction of immunoliposomes with tumor 
cells instead of interaction with T-cells. It is reported that 
binding-site barrier phenomenon is common when proteins 
with higher affinities are used, resulting in higher affinity 
molecules binding to the first molecules in line and not pen-
etrating deeper in the tissue.19 Fujimori et al59 reported by a 
mathematical model showing that high-affinity monoclonal 
antibodies and their interactions with tumor antigens may 
affect their localization in tumors eventually. Adams et al60 
demonstrated the binding-site barrier phenomenon by con-
structing high-affinity variants of antibody fragments (scFv) 
and testing them in vivo. They showed that higher affinity 
of scFv toward the tumor antigens limits its localization and 
diffusion into tumors. High affinity of scFv is another factor 
affecting the scFv movement within tumor in addition to its 
size, avidity, and tumor hydrostatic pressure.60
Apart from the potential this novel formulation shows, 
production of optimal conjugated immunoliposomes is a 
laborious process. Therefore, an optimized protocol with 
robust, reliable, and easy to conduct screening as we provide 
here is imperative. We show that using validated batches 
of immunoliposomes results in consistent in vitro target-
ing performance. In future, these immunoliposomes can be 
exploited for delivering compounds to the tumor microenvi-
ronment, to tumor cells, or to the intracellular environment. 
When encapsulating contrast agents, these liposomes can 
be used for imaging and aid in detection of micrometastasis 
and sentinel nodes during surgery. Upon coentrapment of 
therapeutic and imaging molecules, these nanocarriers can be 
used for image-guided drug delivery or immunomodulation. 
Immunoliposomes provide a versatile platform for combina-
tion therapy or transport of immune molecules that can inhibit 
cell growth, proliferation, and survival. After delivery of che-
motherapeutics, liposomes can be used to interfere directly 
(or through the delivery of compounds that interfere with 
protumorigenic pathways) with, for instance, block expres-
sion of AkT and PD-L1 molecules, which have been linked 
with tumor progression.61,62 Sun et al63 showed successful 
siRNA and doxorubicin co-delivery to cells in vitro. With 
these niosomes, siRNA delivery resulted in sensitization of 
tumor cells for doxorubicin. The co-delivery system showed 
increased therapeutic efficacy in vivo.
Conclusion
In this study, we have successfully produced and coupled 
TCR-like antibodies, and scFv Hyb3 and G8, to lipo-
somes. Antibody fragments maintained their functionality 
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postcoupling, as proven by ELISA. Further experiments show 
that these novel immunoliposomes bind to M1/A1-positive 
ADP cells, but also bind to and are internalized by positive 
melanoma cells, hence providing promising data for further 
use of these immunoliposomes. Melanoma-specific immuno-
liposomes can be further used in drug delivery by entrapment 
of therapeutic molecules in the liposome or as imaging agents 
by entrapping contrast agents. These liposomes can also act 
as carriers for viral particles or molecules that are prone to 
degradation. Here, we show that targeted liposomal therapy 
to melanoma using scFv is promising and that scFv-targeted 
immunoliposomes are a novel formulation that can be further 
exploited for the benefit of science.
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Figure S1 pMhc expression on tumor cell lines.
Notes: We determined the expression of Mage a1 and hla-a1 individually on the melanoma cell lines in use by Pcr. expression of hla-a1 is prevalent in all cell lines 
shown in upper gel row, whereas the lower row shows Mage a1 peptide expression.
Abbreviations: pMhc, peptide:Mhc; Mhc, major histocompatibility complex; Mage a1, Melanoma antigen a1; hla-a1, human leukocyte antigen a1; Pcr, polymerase 
chain reaction.
Table S1 stability of immunoliposomes over 2 weeks
Batch 1 Post 1 week Post 2 weeks
Size (nm) PDI Size (nm) PDI Size (nm) PDI
liposomes 80.34 0.048 79.61 0.033 79.36 0.037
liposomes-scFv g8 93.62 0.072 94.82 0.095 97.52 0.068
liposomes-scFv hyb3 94.77 0.078 93.04 0.087 95.64 0.081
Note: size and PDI measurements were made right after the production of liposomes, separation of unbound antibody from bound, and after 1 and 2 weeks of storage at 4°c.
Abbreviations: scFv, single-chain variable fragment; PDI, polydispersity index.
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Figure S2 Off-target binding of liposomes-scFv Hyb3 on APD cells by flow cytometry.
Notes: (A) This panel shows liposomes incubated with aPD cells pulsed with peptide gated against aPD cells without peptide incubated with liposomes at 4°c for 2 hours. 
Solid black line in each histogram indicates APD cells without peptide incubated with respective sample. Blue filled histogram represents APD cells pulsed with peptide 
incubated with nontargeted liposomes, green filled histogram represents APD cells pulsed with peptide incubated with liposomes-scFv Hyb3, red filled histogram represents 
aPD cells pulsed with peptide incubated with liposomes-scFv g8. (B) This panel shows the same samples gated against unstained aPD cells. solid black line in each histogram 
indicates unstained aPD cells without peptide incubation. Blue histogram represents aPD cells pulsed with peptide incubated with nontargeted liposomes, green histogram 
represents aPD cells pulsed with peptide incubated with liposomes-scFv hyb3, red histogram represents aPD cells pulsed with peptide incubated with liposomes-scFv g8.
Abbreviation: scFv, single-chain variable fragment.
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Figure S3 Stability of immunoliposomes over 2 week by flow cytometry.
Notes: (A) First experiment done with a batch of liposomes, 1 week postpreparation, showing a binding of up to 60% with tumor cells at 37°c for 2 hours. (B) same batch 
of liposomes tested on same cells 1 week later, 2 weeks postpreparation, showing decreased binding to cells.
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